P/E ratio for Affimed (AFMD)
P/E ratio as of April 2024 (TTM): -6.18
According to Affimed 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.17646. At the end of 2022 the company had a P/E ratio of -1.95.
P/E ratio history for Affimed from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.95 | -80.35% |
| 2021 | -9.92 | 1.03% |
| 2020 | -9.82 | 100.16% |
| 2019 | -4.91 | -39.19% |
| 2018 | -8.07 | 390.09% |
| 2017 | -1.65 | -2.44% |
| 2016 | -1.69 | -82.08% |
| 2015 | -9.42 | -132.38% |
| 2014 | 29.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Repligen
RGEN | 79.3 | -1,383.31% | 🇺🇸 USA |
 Merrimack Pharmaceuticals MACK | -134 | 2,068.05% | 🇺🇸 USA |
 Agenus
AGEN | -9.76 | 58.10% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | -0.0676 | -98.91% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.